An interventional study of web-based tool (MAP- Management of Active surveillance in Prostate Cancer) and MUSIC website in Prostate Cancer, sponsored by University of Michigan Rogel Cancer Center. Completed at 1 site in United States. Open to male participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.
Sponsored by University of Michigan Rogel Cancer Center · Not applicable, Interventional, and Health services research
This is a pilot evaluation of a patient-centered intervention that enables providers to support men on active surveillance to maximize adherence. Conducted in urology practices, this pilot will measure key patient-reported, provider-reported, and implementation outcomes. Successful completion of this work will inform a subsequent multi-center effectiveness-implementation hybrid design trial and ultimately will improve low-risk cancer management by effectively engaging Primary Care Physicians (PCPs) in care delivery.
6,367 studies on the registry are indexed under Prostatic Neoplasms; 1,397 are open to participants now.
This study's enrollment of 39 is below the median of 58 across 4,821 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →University of Michigan Rogel Cancer Center is the lead sponsor of 316 studies on the registry; 46 are open to participants now.
Of its 46 completed or terminated interventional studies of FDA-regulated products, 30 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patient Inclusion Criteria:
Patient Exclusion Criteria:
PCP Inclusion Criteria:
Urologist and Clinic Staff Inclusion Criteria:
Behavioral: web-based tool (MAP- Management of Active surveillance in Prostate Cancer)
This is usual care and all urologists are encouraged to refer their patients to the patient educational materials on the MUSIC website (http://www.musicurology.com/patientmaterials/).
Behavioral: MUSIC website
A web-based tool with modules on active surveillance education, team based active surveillance care delivery and the role of the PCP, and self-management for cancer anxiety and worry. {may need more detail}
Standard of care educational materials {add more detail}
Feasibility - Recruitment
Defined as the successful recruitment of 40 patients.
Time frame: up to 9 months
Feasibility - Uptake
Defined as the proportion of men who complete the baseline and follow-up surveys out of the total number of patients recruited.
Time frame: up to 6 months
Acceptability - Mean Satisfaction Scores
Acceptability asks the extent to which participants consider the intervention is agreeable. Patients in the intervention arm will answer questions (on a 5-point Likert scale) regarding the use of the tool including: a) the tool provided me the necessary information about being on active surveillance; b) the tool helped me know what tests I needed and when; c) the tool helped me understand what my PCP can do for my active surveillance; d) the tool was easy to use; e) the amount of time it took to go through the website; and f) I would recommend the tool to other patients. We will ask an open-ended question on if the tool should have any other features in future versions. We will additionally collect paradata such as user actions (clicks) and time spent on each webpage. Mean score will be provided from a scale of 1-5 for each question. 5 indicating greater acceptability. The name of the web-based tool being studied is MAP- Management of Active surveillance in Prostate Cancer.
Time frame: up to 4 months
| Milestone | Intervention Website | Control MUSIC Website |
|---|---|---|
| Started | 17 | 18 |
| Completed | 17 | 18 |
| Not completed | 0 | 0 |
Defined as the successful recruitment of 40 patients.
| Participants | Total Study Enrollment |
|---|---|
| Feasibility - Recruitment | 39 |
Defined as the proportion of men who complete the baseline and follow-up surveys out of the total number of patients recruited.
| Participants | Total Study Enrollment |
|---|---|
| Feasibility - Uptake | 30 |
Acceptability asks the extent to which participants consider the intervention is agreeable. Patients in the intervention arm will answer questions (on a 5-point Likert scale) regarding the use of the tool including: a) the tool provided me the necessary information about being on active surveillance; b) the tool helped me know what tests I needed and when; c) the tool helped me understand what my PCP can do for my active surveillance; d) the tool was easy to use; e) the amount of time it took to go through the website; and f) I would recommend the tool to other patients. We will ask an open-ended question on if the tool should have any other features in future versions. We will additionally collect paradata such as user actions (clicks) and time spent on each webpage. Mean score will be provided from a scale of 1-5 for each question. 5 indicating greater acceptability. The name of the web-based tool being studied is MAP- Management of Active surveillance in Prostate Cancer.
| score on a scale | Intervention Website | Control MUSIC Website |
|---|---|---|
| Acceptability- Total | 3.53 ± 0.83 | — |
| MAP Satisfaction 1 - I would recommend the MAP program to other people | 3.70 ± 0.95 | — |
| MAP Satisfaction 2- Using the MAP program helped me learn about active surveillance. | 3.30 ± 1.34 | — |
| MAP Satisfaction 3- The MAP program helped me know what tests I needed and when. | 2.80 ± 1.32 | — |
| MAP Satisfaction 5- The program helped me understand what my PCP can do for my active surveillance. | 3.40 ± 1.35 | — |
| MAP Satisfaction 8- The MAP program took too much time. | 4.40 ± 0.70 | — |
| MAP Satisfaction 12- The MAP program was easy to use. | 3.60 ± 1.17 | — |
Collected over Patients were monitored while on study for an average of 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intervention Website | 0/17 (0%) | 0/17 (0%) | 0/17 (0%) |
| Control MUSIC Website | 0/18 (0%) | 0/18 (0%) | 0/18 (0%) |
| Age, Customized(years) | Intervention Website | Control MUSIC Website | Total |
|---|---|---|---|
| Mean | 69.3 ± 6.1 | 68.2 ± 7.9 | 68.7 ± 7.0 |
| Sex: Female, Male(Participants) | Intervention Website | Control MUSIC Website | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 17 | 18 | 35 |
| Ethnicity (NIH/OMB)(Participants) | Intervention Website | Control MUSIC Website | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 16 | 18 | 34 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Intervention Website | Control MUSIC Website | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 16 | 17 | 33 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(participants) | Intervention Website | Control MUSIC Website | Total |
|---|---|---|---|
| United States | 17 | 18 | 35 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: Undecided
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Michigan Rogel Cancer Center